317 related articles for article (PubMed ID: 25582740)
1. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.
Choe JH; Overman MJ; Fournier KF; Royal RE; Ohinata A; Rafeeq S; Beaty K; Phillips JK; Wolff RA; Mansfield PF; Eng C
Ann Surg Oncol; 2015 Aug; 22(8):2578-84. PubMed ID: 25582740
[TBL] [Abstract][Full Text] [Related]
2. Impact of adjuvant chemotherapy on outcomes in appendiceal cancer.
Kolla BC; Petersen A; Chengappa M; Gummadi T; Ganesan C; Gaertner WB; Blaes A
Cancer Med; 2020 May; 9(10):3400-3406. PubMed ID: 32189461
[TBL] [Abstract][Full Text] [Related]
3. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery.
Uemura M; Qiao W; Fournier K; Morris J; Mansfield P; Eng C; Royal RE; Wolff RA; Raghav K; Mann GN; Overman MJ
BMC Cancer; 2017 May; 17(1):331. PubMed ID: 28506255
[TBL] [Abstract][Full Text] [Related]
4. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin.
Munoz-Zuluaga CA; King MC; Ledakis P; Gushchin V; Sittig M; Nieroda C; Zambrano-Vera K; Sardi A
Eur J Surg Oncol; 2019 Sep; 45(9):1598-1606. PubMed ID: 31109821
[TBL] [Abstract][Full Text] [Related]
5. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
[TBL] [Abstract][Full Text] [Related]
6. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
7. Clinical findings of patients with pseudomyxoma peritonei of appendiceal origin undergoing Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Iavazzo C; Spiliotis J
Updates Surg; 2020 Sep; 72(3):923-924. PubMed ID: 32602012
[No Abstract] [Full Text] [Related]
8. Early postoperative intraperitoneal chemotherapy following cytoreductive surgery for appendiceal mucinous neoplasms with isolated peritoneal metastasis.
Wagner PL; Jones D; Aronova A; Shia J; Weiser MR; Temple LK; Chung KY; O'Reilly EM; Kelsen D; Paty PB; Nash GM
Dis Colon Rectum; 2012 Apr; 55(4):407-15. PubMed ID: 22426264
[TBL] [Abstract][Full Text] [Related]
9. CA 19-9 to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with epithelial appendiceal mucinous neoplasms and peritoneal dissemination undergoing cytoreduction surgery and intraperitoneal chemotherapy: A retrospective cohort study.
Kozman MA; Fisher OM; Rebolledo BJ; Valle SJ; Alzahrani N; Liauw W; Morris DL
Eur J Surg Oncol; 2017 Dec; 43(12):2299-2307. PubMed ID: 28993033
[TBL] [Abstract][Full Text] [Related]
10. Early Postoperative Intraperitoneal Chemotherapy for Low-Grade Appendiceal Mucinous Neoplasms with Pseudomyxoma Peritonei: Is it Beneficial?
Huang Y; Alzahrani NA; Liauw W; Traiki TB; Morris DL
Ann Surg Oncol; 2017 Jan; 24(1):176-183. PubMed ID: 27718032
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathological features and prognosis of primary appendiceal adenocarcinoma].
Liang JW; Wang Z; Zhou ZX; Zhang XM; Hu JJ; Zhao P
Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):616-9. PubMed ID: 23158998
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy.
Chua TC; Chong CH; Liauw W; Zhao J; Morris DL
Ann Surg; 2012 Aug; 256(2):342-9. PubMed ID: 22750758
[TBL] [Abstract][Full Text] [Related]
13. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL
J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection.
Grotz TE; Overman MJ; Eng C; Raghav KP; Royal RE; Mansfield PF; Mann GN; Robinson KA; Beaty KA; Rafeeq S; Matamoros A; Taggart MW; Fournier KF
Ann Surg Oncol; 2017 Sep; 24(9):2646-2654. PubMed ID: 28695394
[TBL] [Abstract][Full Text] [Related]
15. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
16. Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin.
Winer J; Zenati M; Ramalingam L; Jones H; Zureikat A; Holtzman M; Lee K; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2014 May; 21(5):1456-62. PubMed ID: 24201745
[TBL] [Abstract][Full Text] [Related]
17. Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei.
Bjersand K; Mahteme H; Sundström Poromaa I; Andréasson H; Graf W; Larsson R; Nygren P
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S810-6. PubMed ID: 26193962
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.
van Eden WJ; Kok NFM; Snaebjornsson P; Jóźwiak K; Woensdregt K; Bottenberg PD; Boot H; Aalbers AGJ
BJS Open; 2019 Jun; 3(3):376-386. PubMed ID: 31183454
[TBL] [Abstract][Full Text] [Related]
19. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base.
Asare EA; Compton CC; Hanna NN; Kosinski LA; Washington MK; Kakar S; Weiser MR; Overman MJ
Cancer; 2016 Jan; 122(2):213-21. PubMed ID: 26506400
[TBL] [Abstract][Full Text] [Related]
20. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
Rovers KP; Bakkers C; Nienhuijs SW; Burger JWA; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; van Meerten E; Tuynman JB; Kusters M; Versteeg KS; Aalbers AGJ; Kok NFM; Buffart TE; Wiezer MJ; Boerma D; Los M; de Reuver PR; Bremers AJA; Verheul HMW; Kruijff S; de Groot DJA; Witkamp AJ; van Grevenstein WMU; Koopman M; Nederend J; Lahaye MJ; Kranenburg O; Fijneman RJA; van 't Erve I; Snaebjornsson P; Hemmer PHJ; Dijkgraaf MGW; Punt CJA; Tanis PJ; de Hingh IHJT;
JAMA Surg; 2021 Aug; 156(8):710-720. PubMed ID: 34009291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
